Therapeutic efficacy of a novel βiii/βiv-tubulin inhibitor (veru-111) in pancreatic cancer

HIGHLIGHTS

• who: Vivek K. Kashyap from the (UNIVERSITY) have published the Article: Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer, in the Journal: (JOURNAL)
• what: VERU-111 Conclusions: This study has identified an of which appears to have excellent potential as monotherapy or in combination with conventional therapeutic regimens for PanCa treatment. The authors have shown that a novel synthetic molecule that is known to overcome multidrug resistance preferentially inhibits the expression of βIII and βIV-tubulins via restoring the expression of miR-200c in PanCa cells . In this experiment . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.